Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Non-Current Assets (2016 - 2025)

BioCorRx (BICX) has disclosed Non-Current Assets for 15 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 397.39% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.2 million through Dec 2025, up 1955.2% year-over-year, with the annual reading at $1.3 million for FY2025, 397.39% up from the prior year.
  • Non-Current Assets hit $1.3 million in Q4 2025 for BioCorRx, down from $7.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $7.5 million in Q3 2025 to a low of $165851.0 in Q1 2024.
  • Historically, Non-Current Assets has averaged $1.4 million across 5 years, with a median of $504102.5 in 2022.
  • Biggest five-year swings in Non-Current Assets: plummeted 55.13% in 2023 and later skyrocketed 3659.57% in 2025.
  • Year by year, Non-Current Assets stood at $591649.0 in 2021, then fell by 23.99% to $449684.0 in 2022, then tumbled by 55.13% to $201768.0 in 2023, then surged by 32.8% to $267945.0 in 2024, then skyrocketed by 397.39% to $1.3 million in 2025.
  • Business Quant data shows Non-Current Assets for BICX at $1.3 million in Q4 2025, $7.5 million in Q3 2025, and $6.2 million in Q2 2025.